Melanie Schroeder1, Katie Hall2, Lina Eliasson2, Sophia Bracey3, Necdet B Gunsoy4, Jake Macey3, Paul W Jones5, Afisi S Ismaila6,7. 1. Value Evidence and Outcomes, GlaxoSmithKline plc., Brentford, United Kingdom. 2. Patient Centred Outcomes, ICON plc., London, United Kingdom. 3. Patient Centred Outcomes, ICON plc., Abingdon, United Kingdom. 4. Value Evidence and Outcomes, GlaxoSmithKline plc., Uxbridge, United Kingdom. 5. Global Respiratory Therapy Area, GlaxoSmithKline plc., Brentford, United Kingdom. 6. Value Evidence and Outcomes, GlaxoSmithKline plc., Collegeville, Pennsylvania, United States. 7. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: A wide range of therapeutic regimens, including single-inhaler triple therapies (SITTs), are now available for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Thus, an improved understanding of patient preferences may be valuable to inform physician prescribing decisions. This study was performed to assess the factors considered by patients when making decisions about their COPD treatments using qualitative techniques. METHODS: In the United Kingdom, United States and Germany, individual qualitative interviews (n=10 per country) and focus groups (1 per country; [United Kingdom, n=4; United States, n=6; Germany, n=6 participants]) were conducted. Interviews and focus groups were semi‑structured, lasting approximately 60 minutes, and focused on treatment preferences. Data were analyzed according to emerging themes identified from the interviews; qualitative thematic analysis of the data was performed using specialist software. RESULTS: In interviews and focus groups, efficacy, ease of use, and lower frequency of use were favored attributes for current treatment, while side effects, medication taste, and more complex administration techniques were key dislikes. In interviews, most participants would consider a switch in medication, mainly for improved efficacy, but also to reduce medication frequency or following physician advice. Overall, efficacy and ease of use were the 2 most important attributes reported in interviews in all 3 countries. CONCLUSION: Patients with COPD have preferences for certain attributes of medication, highlighting the multi-faceted nature of treatment effectiveness and the importance of the delivery device.These results were subsequently used to inform the design of a discrete choice experiment. JCOPDF
BACKGROUND: A wide range of therapeutic regimens, including single-inhaler triple therapies (SITTs), are now available for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Thus, an improved understanding of patient preferences may be valuable to inform physician prescribing decisions. This study was performed to assess the factors considered by patients when making decisions about their COPD treatments using qualitative techniques. METHODS: In the United Kingdom, United States and Germany, individual qualitative interviews (n=10 per country) and focus groups (1 per country; [United Kingdom, n=4; United States, n=6; Germany, n=6 participants]) were conducted. Interviews and focus groups were semi‑structured, lasting approximately 60 minutes, and focused on treatment preferences. Data were analyzed according to emerging themes identified from the interviews; qualitative thematic analysis of the data was performed using specialist software. RESULTS: In interviews and focus groups, efficacy, ease of use, and lower frequency of use were favored attributes for current treatment, while side effects, medication taste, and more complex administration techniques were key dislikes. In interviews, most participants would consider a switch in medication, mainly for improved efficacy, but also to reduce medication frequency or following physician advice. Overall, efficacy and ease of use were the 2 most important attributes reported in interviews in all 3 countries. CONCLUSION: Patients with COPD have preferences for certain attributes of medication, highlighting the multi-faceted nature of treatment effectiveness and the importance of the delivery device.These results were subsequently used to inform the design of a discrete choice experiment. JCOPDF
Authors: Andrew P Yu; Annie Guérin; Diego Ponce de Leon; Karthik Ramakrishnan; Eric Q Wu; Michelle Mocarski; Steve Blum; Juliana Setyawan Journal: J Med Econ Date: 2011-06-16 Impact factor: 2.448
Authors: David A Lipson; Frank Barnhart; Noushin Brealey; Jean Brooks; Gerard J Criner; Nicola C Day; Mark T Dransfield; David M G Halpin; MeiLan K Han; C Elaine Jones; Sally Kilbride; Peter Lange; David A Lomas; Fernando J Martinez; Dave Singh; Maggie Tabberer; Robert A Wise; Steven J Pascoe Journal: N Engl J Med Date: 2018-04-18 Impact factor: 91.245
Authors: David A Lipson; Helen Barnacle; Ruby Birk; Noushin Brealey; Nicholas Locantore; David A Lomas; Andrea Ludwig-Sengpiel; Rajat Mohindra; Maggie Tabberer; Chang-Qing Zhu; Steven J Pascoe Journal: Am J Respir Crit Care Med Date: 2017-08-15 Impact factor: 21.405
Authors: Hana Müllerová; Sarah H Landis; Zaurbek Aisanov; Kourtney J Davis; Masakazu Ichinose; David M Mannino; Joe Maskell; Ana M Menezes; Thys van der Molen; Yeon-Mok Oh; Maggie Tabberer; MeiLan K Han Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-04-27
Authors: Nicolas Roche; Philippe Devillier; Patrick Berger; Arnaud Bourdin; Daniel Dusser; Jean-François Muir; Yan Martinat; Philippe Terrioux; Bruno Housset Journal: ERJ Open Res Date: 2021-12-13